AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Jade Biosciences, Inc. Common Stock
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG00WGHZFJ2
14.59▼ 0.32 (-2.15%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
—
EV / Revenue
—
EV / EBITDA
Financial Highlights
Revenue (TTM)
—
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
—
Net Debt
Trading Information
Previous Close
14.91
Day's Range
14.54 – 15.00
52-Week Range
8.36 – 28.00
Volume
634.4K
Avg Volume
980.9K
Share Statistics
Shares Outstanding
Employees
55
Exchange
XNAS
Listed
2025-04-29
Share count as of August 3, 2026

Jade Biosciences, Inc. Common Stock (JBIO) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Jade Biosciences, Inc. Common Stock (JBIO)
What is Jade Biosciences, Inc. Common Stock's Market Cap?
Jade Biosciences, Inc. Common Stock's Market Cap is $927.9M, based on as-reported figures from SEC (XBRL) filings.
What is Jade Biosciences, Inc. Common Stock's Enterprise Value?
Jade Biosciences, Inc. Common Stock's Enterprise Value is $466.7M, based on as-reported figures from SEC (XBRL) filings.
What is Jade Biosciences, Inc. Common Stock's EV / EBITDA?
Jade Biosciences, Inc. Common Stock's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Jade Biosciences, Inc. Common Stock's Net Income (TTM)?
Jade Biosciences, Inc. Common Stock's Net Income (TTM) is -$153.2M, based on as-reported figures from SEC (XBRL) filings.
What is Jade Biosciences, Inc. Common Stock's EBITDA?
Jade Biosciences, Inc. Common Stock's EBITDA is -$164.7M, based on as-reported figures from SEC (XBRL) filings.
What is Jade Biosciences, Inc. Common Stock's Diluted EPS (TTM)?
Jade Biosciences, Inc. Common Stock's Diluted EPS (TTM) is -2.41, based on as-reported figures from SEC (XBRL) filings.
What is Jade Biosciences, Inc. Common Stock's Net Debt?
Jade Biosciences, Inc. Common Stock's Net Debt is -$461.2M, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · JBIOAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Operating expenses:
Research and development
General and administrative
Total operating expenses
Loss from operations—
Other income (expense):
Interest income
Change in fair value of Convertible Notes payable
Other expense
Total other income (expense), net
Net loss before income tax expense——
Net loss
Net loss per share attributable to common stockholders, basic—
Net loss per share attributable to common stockholders, diluted—